# Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC

> **NCT03133234** · — · COMPLETED · sponsor: **AstraZeneca** · enrollment: 47 (actual)

## Conditions studied

- T790M Positive NSCLC Patients

## Interventions

- **DRUG:** osimertinib

## Key facts

- **NCT ID:** NCT03133234
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-23
- **Primary completion:** 2017-09-13
- **Final completion:** 2017-09-13
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2018-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03133234

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03133234, "Effect of Osimertinib in Ethnic Chinese With EGFR and T790M Mutated NSCLC". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03133234. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*